Chronic Kidney Disease

Chronic kidney disease has emerged as one of the leading noncommunicable causes of mortality worldwide. As the prevalence is increasing due to the close association with highly common disorders such as diabetes mellitus, heart failure and hypertension and available treatments are limited in their effectiveness, there is an urgent need for new and better treatment options.

Recruitment and retention for Chronic Kidney Disease clinical trials can be challenging, and effective protocol design and conduct are essential for ensuring high-quality data and reliable outcomes in a timely manner. Julius Clinical is experienced in conducting CKD clinical trials, and our proprietary site networks and close collaboration with leading scientific experts ensure the best support for your trial.

Meet our leader for CKD clinical trials

Prof. Dr. Hiddo Lambers Heerspink is our Associated Scientific Leader for kidney disease clinical trials. Prof. Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of kidney and cardiovascular diseases in patients with diabetes with a specific focus on personalized medicine. He has successfully led and currently leads numerous clinical trials with new interventions to reduce diabetes related kidney and cardiovascular complications.

Chronic kidney disease and heart disease are closely interrelated. Our proprietary Cardio Clinical network exists of 833 sites in 20 different countries, providing access to pioneering expertise and capabilities for CKD research and trials around the world. The network has been involved in various large-scale clinical trials and has extensive experienced staff in performing such trials.

Read more

A selection of our Chronic Kidney Disease trials

Whether your study involves specific clinical trial phases, an investigator-initiated trial, observational study or tailor-made trial, we have years of experience in clinical trials and the expertise you need wherever it’s required.


Phase III, Global

11,000 Patients | >20 Countries

The effects of routine antihypertensive therapy and glucose control therapy in patients with type II diabetes.


1360 Patients | 8 Countries | 62 Sites

Comparing high-dose Haemodiafiltration (HDF) versus conventional high-flux Haemodialysis (HD).

Our expert team for Chronic Kidney Disease

Our in-house team for Chronic Kidney Disease is highly experienced in conducting clinical trials for kidney, heart and metabolic diseases. Their insights and dedication will make the difference for your clinical trial.

Rick grobbee
Marco alings
Manuel castro cabezas
Marcel bootsma
Elizabeth liano callahan

News & webinars

CKD Resources

Explore our Chronic Kidney Disease case studies.


"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.


Twitter Facebook LinkedIn